Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 PEG Ratio is 0.42 as of Sep. 01, 2026, which is at its 10-year median of 0.42. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 37 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 89.19% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for WuXi XDC Cayman's PEG Ratio or its related term are showing as below:
STU:L74'
s PEG Ratio Range Over the Past 10 Years
Min: 0.33 Med: 0.42 Max: 0.51
Current: 0.43
During the past 6 years, WuXi XDC Cayman's highest PEG Ratio was 0.51. The lowest was 0.33. And the median was 0.42.
STU:L74's PEG Ratio is ranked better than 89.19% of 37
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.62
vs STU:L74: 0.43
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
WuXi XDC Cayman PEG Ratio Related Terms
WuXi XDC Cayman PEG Ratio Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's PEG Ratio distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
WuXi XDC Cayman (STU:L74) has a PEG Ratio of 0.42 as of Sep. 01, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 0.42. Over the past decade, WuXi XDC Cayman's PEG Ratio has ranged from 0.33 to 0.51. According to the industry distribution chart, WuXi XDC Cayman ranks #4 out of 37 companies in the Medical Diagnostics & Research industry, placing it in the top 10.8%.
Is WuXi XDC Cayman's PEG Ratio too high?
WuXi XDC Cayman's current PEG Ratio of 0.42 is near median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.51. The Medical Diagnostics & Research industry median PEG Ratio is 2.62. WuXi XDC Cayman's value of 0.42 is 84% below this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #4 out of 37 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #4 out of 37 companies for PEG Ratio. This places WuXi XDC Cayman in the top 11% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 2.62. WuXi XDC Cayman's value of 0.42 is 84% below this benchmark. Historically, WuXi XDC Cayman's own PEG Ratio has ranged from 0.33 to 0.51 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 2.62, WuXi XDC Cayman has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.62, based on 37 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current PEG Ratio of 0.42 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current PEG Ratio is 0.42, which is near median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current PEG Ratio of 0.42. The current PEG Ratio is 0.42, which is near median its 10-year median of 0.42 and 84% below the Medical Diagnostics & Research industry median of 2.62. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current PEG Ratio is 0.42 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
